Low number of omental preadipocytes with high leptin and low adiponectin secretion is associated with high fasting plasma glucose levels in obese subjects

2006 ◽  
Vol 8 (5) ◽  
pp. 585-588 ◽  
Author(s):  
A. H. F. Bakker ◽  
J. Nijhuis ◽  
W. A. Buurman ◽  
F. M. H. van Dielen ◽  
J. W. M. Greve
2019 ◽  
Vol 8 (9) ◽  
pp. 1436 ◽  
Author(s):  
Chun-Chung Lin ◽  
Kai-Pi Cheng ◽  
Hao-Chang Hung ◽  
Chung-Hao Li ◽  
Ching-Han Lin ◽  
...  

Secretogranin III (SCG3) plays a crucial role in the biogenesis of secretory granules in endocrine cells, and thus affects glucose homeostasis by regulating insulin secretion by pancreatic beta cells. Insulin resistance and compensatory hyperinsulinemia are hallmarks of metabolic syndrome (MetS). However, the role of SCG3 in MetS remains unclear. Therefore, we investigated the relationship between serum SCG3 levels and metabolic parameters in subjects with and without MetS. This was a case control study, and 295 subjects were recruited. Serum SCG3 concentrations were compared between groups. Associations between SCG3 levels and clinico-metabolic parameters were also examined. We found serum SCG3 levels were higher in the MetS group than non-MetS group (122.6 ± 79.2 vs. 90.6 ± 58.5 nmol/L, p = 0.009). Specifically, elevated SCG3 levels were found in subjects with high fasting plasma glucose (FPG) levels, central obesity, or hypertriglyceridemia. Additionally, MetS was an independent factor of serum SCG3 levels in multivariate linear regression analyses. Moreover, FPG, free fatty acids, and waist circumference were positively associated with serum SCG3 concentrations after adjusting for insulin levels, high-sensitivity C-reactive protein, and cardiovascular risk factors. In conclusion, serum SCG3 concentrations were higher in subjects with MetS and were independently associated with FPG levels.


2020 ◽  
Vol 169 ◽  
pp. 108448
Author(s):  
Yun Huang ◽  
Heming Guo ◽  
Yan Zhou ◽  
Jingjing Guo ◽  
Tiantian Wang ◽  
...  

2021 ◽  
Vol 11 ◽  
Author(s):  
Shangbo Xu ◽  
Yiyuan Liu ◽  
Taofeng Zhang ◽  
Jiehua Zheng ◽  
Weixun Lin ◽  
...  

BackgroundThe burden of breast cancer has been increasing globally. The epidemiology burden and trends need to be updated. This study aimed to update the burden and trends of breast cancer incidences, deaths, and disability-adjusted life-years (DALYs) from 1990 to 2019, using the Global Burden of Disease 2019 study.MethodsThe data of incidences, deaths, DALYs, and age-standardized rates were extracted. Estimated annual percentage changes were used to quantify the trends of age-standardized rates. Besides, the population attributable fractions of the risk factors of breast cancer were also estimated.ResultsGlobally, the incidences of breast cancer increased to 2,002,354 in 2019. High social-development index (SDI) quintiles had the highest incidence cases with a declining trend in age-standardized incidence rate. In 2019, the global deaths and DALYs of breast cancer increased to 700,660 and 20,625,313, respectively. From 1990 to 2019, the age-standardized mortality rates and age-standardized DALY rates declined globally, especially in high and high-middle SDI quintiles. Besides, the trends varied from different regions and countries. The proportion of the patients in the 70+ years age group increased globally. Deaths of breast cancer attributable to high fasting plasma glucose and high body mass index increased globally, and high fasting plasma glucose was the greatest contributor to the global breast cancer deaths.ConclusionThe burden of breast cancer in higher SDI quintiles had gone down while the burden was still on the rise in lower SDI quintiles. It is necessary to appeal to the public to decrease the exposure of the risk factors.


2003 ◽  
Vol 23 (6) ◽  
pp. 640-642 ◽  
Author(s):  
BB Afolabi ◽  
OO Abudu ◽  
O Oyeyinka

2020 ◽  
Vol 12 (11) ◽  
pp. 807-818
Author(s):  
Lingxia Ye ◽  
Jingya Xu ◽  
Tianyue Zhang ◽  
Xiling Lin ◽  
Xiaowen Pan ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document